Albendazole treatment of human hydatid tissue.
The effect of albendazole was studied in 12 patients with cystic hydatid disease (CHD) of the liver. Six patients received albendazole continuously for 6 months, while 6 patients received albendazole for 6 courses of 4 weeks with a 2 week drug-free interval between cycles. The continuous therapy proved successful, with stable involution at the follow-up at 24 months, while the patients treated with discontinuous therapy showed improvement or relapse. In our experience, continuous therapy was more effective and can be considered to be a suitable alternative or percutaneous therapy in uncomplicated hydatid liver disease, as an initial treatment.
Luchi
S
S
Department of Infectious Diseases, Pisa Hospital, Italy.
Vincenti
A
A
Messina
F
F
Parenti
M
M
Scasso
A
A
Campatelli
A
A
D000328:Adult; D000368:Aged; D015766:Albendazole / Q000627:therapeutic use*; D004443:Echinococcosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D015766:Albendazole